Grandfield & Dodd’s Novo Nordisk NVO Stock Holding History

Grandfield & Dodd’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$313K	Sell	8,507 -25	-0.3%	-$1.19K	0.02%	176
2025 Q4	$434K	Buy	8,532 +25	+0.3%	+$1.28K	0.02%	151
2025 Q3	$472K	Hold	8,507	–	–	0.03%	144
2025 Q2	$587K	Buy	8,507 +173	+2%	+$11.8K	0.03%	128
2025 Q1	$579K	Sell	8,334 -150	-2%	-$12.4K	0.04%	130
2024 Q4	$730K	Sell	8,484 -50	-0.6%	-$5.41K	0.05%	120
2024 Q3	$1.02M	Sell	8,534 -20	-0.2%	-$2.67K	0.06%	110
2024 Q2	$1.22M	Sell	8,554 -2,200	-20%	-$292K	0.08%	102
2024 Q1	$1.38M	Sell	10,754 -1,980	-16%	-$236K	0.09%	101
2023 Q4	$1.32M	Buy	12,734 +100	+0.8%	+$9.89K	0.09%	95
2023 Q3	$1.15M	Hold	12,634	–	–	0.08%	98
2023 Q2	$1.02M	Sell	12,634 -900	-7%	-$73.5K	0.07%	102
2023 Q1	$1.08M	Buy	13,534 +200	+1%	+$14.2K	0.08%	101
2022 Q4	$902K	Hold	13,334	–	–	0.07%	108
2022 Q3	$660K	Sell	13,334 -100	-0.7%	-$5.36K	0.05%	119
2022 Q2	$750K	Hold	13,434	–	–	0.06%	112
2022 Q1	$750K	Hold	13,434	–	–	0.05%	121
2021 Q4	$750K	Hold	13,434	–	–	0.05%	118
2021 Q3	$640K	Buy	13,434 +1,100	+9%	+$53.2K	0.04%	121
2021 Q2	$520K	Hold	12,334	–	–	0.04%	128
2021 Q1	$420K	Hold	12,334	–	–	0.03%	141
2020 Q4	$430K	Hold	12,334	–	–	0.03%	133
2020 Q3	$430K	Hold	12,334	–	–	0.04%	132
2020 Q2	$400K	Hold	12,334	–	–	0.04%	137
2020 Q1	$371K	Hold	12,334	–	–	0.04%	129
2019 Q4	$357K	Hold	12,334	–	–	0.03%	142
2019 Q3	$319K	Hold	12,334	–	–	0.03%	146
2019 Q2	$315K	Hold	12,334	–	–	0.03%	151
2019 Q1	$323K	Hold	12,334	–	–	0.03%	145
2018 Q4	$284K	Hold	12,334	–	–	0.03%	145
2018 Q3	$291K	Hold	12,334	–	–	0.03%	154
2018 Q2	$284K	Hold	12,334	–	–	0.03%	156
2018 Q1	$304K	Hold	12,334	–	–	0.03%	151
2017 Q4	$331K	Hold	12,334	–	–	0.04%	153
2017 Q3	$297K	Hold	12,334	–	–	0.03%	159
2017 Q2	$265K	Hold	12,334	–	–	0.03%	167
2017 Q1	$211K	Hold	12,334	–	–	0.03%	178
2016 Q4	$221K	Sell	12,334 -2,400	-16%	-$43.5K	0.03%	174
2016 Q3	$306K	Hold	14,734	–	–	0.04%	154
2016 Q2	$396K	Sell	14,734 -720	-5%	-$19.7K	0.06%	129
2016 Q1	$419K	Hold	15,454	–	–	0.06%	116
2015 Q4	$449K	Sell	15,454 -916	-6%	-$25.4K	0.07%	113
2015 Q3	$444K	Hold	16,370	–	–	0.07%	114
2015 Q2	$448K	Hold	16,370	–	–	0.07%	118
2015 Q1	$437K	Sell	16,370 -112	-0.7%	-$2.58K	0.07%	122
2014 Q4	$349K	Sell	16,482 -80	-0.5%	-$1.79K	0.05%	131
2014 Q3	$394K	Buy	16,562 +80	+0.5%	+$1.84K	0.06%	120
2014 Q2	$381K	Hold	16,482	–	–	0.06%	138
2014 Q1	$376K	Buy	16,482 +12	+0.1%	+$256	0.06%	137
2013 Q4	$304K	Sell	16,470 -590	-3%	-$10.3K	0.05%	142
2013 Q3	$289K	Hold	17,060	–	–	0.05%	140
2013 Q2	$264K	Buy	+17,060	New	+$284K	0.05%	151

Other funds holding NVO

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Grandfield & Dodd's NVO Position: Q1 2026 in Review

Grandfield & Dodd reduced its Novo Nordisk (NVO) stake by 0.29% in Q1 2026, selling an estimated $1.19K and leaving 8,507 shares worth $313K. The position accounts for 0.02% of the portfolio, ranked #176.

Grandfield & Dodd first reported a position in NVO in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.38M in Q1 2024. 1,273 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

Grandfield & Dodd held 8,507 shares of Novo Nordisk worth $313K as of Q1 2026.
Grandfield & Dodd sold 25 Novo Nordisk shares in Q1 2026, an estimated $1.19K.
Novo Nordisk made up 0.02% of Grandfield & Dodd's portfolio in Q1 2026, its #176 holding.
Grandfield & Dodd first reported a position in Novo Nordisk in Q2 2013 and has held it in 52 quarters since.
Grandfield & Dodd's Novo Nordisk position peaked at $1.38M in Q1 2024.
1,273 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Grandfield & Dodd's 13F filing for Q1 2026, filed 7 May 2026.